|Butyrate 600 mg 250 Cap|
Quantity in Basket:
Free Shipping to All US Addresses
Manufacturer: E Lyte BodyBio
Mfr Code: SP325
Butyrate is a short chain fatty acid that is a potent detoxifier of ammonia and neurotoxins. It encourages the formation of friendly bacteria in the gut.
What exactly is Butyrate?
Butyrate is a short chain fatty acid (SCFA) that has been combined with calcium & magnesium. It is made in the lower colon by bacteria and taken up by the colonocytes, the cells that line the colon. It then becomes an important food for those cells. Lacking good bacteria in our colon, such as when we take antibiotics, can lead to an insufficient supply of butyrate.
What is Butyrate used for?
Butyrate scrubs & cleans the liver, the gall bladder and the biliary tree. It also cleans the bowel, controls ammonia, removes ‘renegade’ fats (the very long ones that accumulate with age) and lowers the expression of inflammatory immune markers called cytokines.
What is the recommended dosage of Butyrate?
Approximately 2-3 caps daily, unless otherwise suggested by a HCP.
How long will 1 bottle of Butyrate last?
It depends on how many you take daily - they are sold in 100 or 250 count bottles.
Can Butyrate be taken on an empty stomach?
We have never heard of any problems taking Butyrate on an empty stomach.
What are the ingredients in Butyrate?
Butyric Acid, Calcium Hydroxide, Magnesium Hydroxide, and Diglycerides
Are there any side effects from taking Butyrate?
None to our knowledge.
Short chain fatty acids (SCFAs) acetate, propionate, and butyrate are the end products of anaerobic bacteria break down of carbohydrates in the colon. They may be paying us back, like rent, for providing them with a secure haven in the colon by producing butyrate. The process is basically fermentation and is an important function of the large bowel. Butyrate is manufactured by many of the normal microflora out of fully digested vegetable fiber and appears to be the number one fuel for the cells that line the colon. The production and absorption of SCFAs are closely related to the nourishment of colonic mucosa with a considerable amount of energy as a byproduct derived from carbohydrate break down.
Butyrate is readily metabolized by our colonocytes, is easily absorbed by intestine, stimulates sodium and water absorption in the colon, and is critical to the intestinal mucosa. Butyrate has been demonstrated clinically to be useful in sequestering and controlling ammonia in hyperammonemia as in patients with seizure disorders, brain fog and stroke. Rudolfo Brenner has proposed that butyrate clears the liver of renegade fatty acids (odd and very long chain FA) and is a primary adjunct in states of toxicity.
The interest in the effects of SCFAs, i.e. butyrate in the human organism, has been rising in the last ten years, particularly as to the relevance of the physiological function of butyrate and dietary fibers and their possible role in intestinal neoplasia (cancer).
Anti-bacterial: Butyric acid is released from milk by pre-intestinal lipases during suckling. It is also known to inhibit bacterial growth, and may be a significant factor in controlling bacterial growth in the stomach of pre-weaned animals (Sun CQ 1998).
Bacteria Enhancement: Butyrate is a short chain fatty acid derived from the metabolism of intestinal contents by gut bacteria. Butyrate concent-rations reflect, therefore, the bacterial microenvironment established within the intestine (Fusunyan RD, 1998).
Anti-inflammatory: Butyrate decreases proinflammatory cytokine expression via inhibition of NFkappaB activation and IkappaB alpha degradation. These anti-inflammatory properties provide a rationale for assessing butyrate in the treatment of Crohns Disease (Segain JP 2000).
Mucosal Health: The effect of the topical corticosteroid clobetasone butyrate on enzyme activity and morphology of duodenal mucosa was studied in 9 patients with celiac disease and 10 controls using organ culture techniques. There was significant increase in mucosal alkaline phosphatase, lactase and maltase activities, but inclusion of a soluble extract of gluten reduced this effect (Bramble MG 1983). This reverse reaction reinforces wide clinical experience as to the negative effects of dietary gluten.
Stomach Ulcers (H.pylori): Amelioration of persistent infection with H. pylori in mice was demonstrated following infection with C. butyricum. The probiotic agent, C. butyricum MIYAIRI 588 may have some beneficial effects on H. pylori infection (Takahashi M. 2000).
Diarrhia Control: Selective down regulation of NKCC1 gene expression and function by butyrate leads to a profound decrease in transepithelial Chloride (Cl-) secretion. The concentration of cellular Cl- is directly linked to the control of edema and diarrhea. These data emphasize the importance of NKCC1 in determining epithelial secretory capacity and suggest the possible use of butyrate as a therapy for diarrheal disorders (Matthews JB 1998).
Spinal Muscular Atrophy: Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, leading to muscular paralysis with muscular atrophy. No effective treatment of this disorder is presently available. Oral administration of sodium butyrate decreased the birth rate of severe types of SMA-like mice, and SMA symptoms were ameliorated for all three types of SMA-like mice. These results suggest that sodium butyrate may be an effective drug for the treatment of human SMA patients (Chang JG 2001).
PPAR-g (Gene Expression): The peroxisome proliferator-activated receptor (PPAR)-gamma is a nuclear lipid-activable receptor controlling the expression of genes involved in lipid metabolism and adipocyte differentiation. PPAR-gamma mRNA and protein increased significantly in butyrate-treated Caco-2 cells in a dose- and time-dependent manner. It appears that the level of butyrate in the colon may play a role in gene expression in lipid metabolism. (Wachtershauser A 2000).
Ulcerative Colitis: SCFAs enemas or oral probiotics are a new and promising treatment for ulcerative colitis. The effects have been attributed to the oxidation of SCFAs in the colonocytes and to the ability of butyrate to induce enzymes (i.e. transglutaminase) in promoting mucosal restitution. Evidence is mounting regarding the effects of butyrate on various cell functions, particularly related to cancer prophylaxis and treatment (D'Argenio G 1999).
Colon Cancer: Butyrate is produced in the colon of mammals as a result of microbial fermentation of dietary fiber, undigested starch, and proteins. Butyrate may be an important protective agent in colonic carcinogenesis (Velazquez OC 1996).
Myelogenous Leukemia: Parenteral administration of butyrate (500 mg/kg/day) for ten days to a child with acute myelogenous leukemia in relapse, and resistant to conventional therapy, resulted in elimination of myeloblasts from the peripheral blood, an increase in mature myeloid cells. Bone marrow myeloblasts were reduced from 70-80% to 20% following the course of intravenous butyrate. No impairment of liver or renal function and no coagulation abnormalities were observed during butyrate treatment (Novogrodsky A 1983).
Colon Cancers (3) : Siavoshian compared the effects of acetate, propionate, butyrate, iso-butyrate, valerate , iso-valerate and caproate on cell growth of three human colonic adenocarcinoma cell lines. All are short chain fatty acids (SCFAs) produced by colonocytes in the colon. The study showed that butyrate, propionate and valerate inhibited cell proliferation of the three cancer cell lines (Siavoshian S., 1997)
Antileukemic: Searching for the magic bullet against cancer: the butyrate saga provides more insight into specificity and modalities of action of different butyrate derivatives and may be a guarantee for excellent tailored antileukemic therapy in the future (Santini V 2001).
Glioblastoma: In cell lines and explanted cells, sodium butyrate consistently inhibited glioblastoma cell proliferation (51% +/- 6 that of controls) and migration (46% +/-17). Intratumoral infusion of 40 mmol/L sodium butyrate prolonged the survival of Wistar-Furth rats with intracerebral C6 tumors (P = 0.013) without detectable toxicity (Engelhard HH 2001).
Toxicity: Butyrate clears the liver of renegade fatty acids (odd and very long chain FA) and is a primary adjunct in states of toxicity. (Rudolfo Brenner)
Serving Size: 6 capsules
Amount per serving:
Ingredients: Butyric Acid, Calcium hydroxide, Magnesium hydroxide, and diglycerides.
Keep out of reach of children. Keep in a cool, dry place.